Elevated gatifloxacin and reduced rifampicin concentrations in a single-dose interaction study amongst healthy volunteers

Journal of Antimicrobial Chemotherapy

Volumn 60, Issue 6, 2007, Pages 1398-1401

  Mcilleron, Helen ^a   Norman, Jennifer ^a   Kanyok, Thomas P ^b   Fourie, P Bernard ^c   Horton, John ^d   Smith, Peter J ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c Medicine in Need   (United States)

^d Tropical Projects   (United Kingdom)

Author keywords

Isoniazid; Mycobacterium tuberculosis; Pharmacokinetics; Pyrazinamide

Indexed keywords

AKURIT Z; GATIFLOXACIN; GATISPAN 400; RIFATER; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DROWSINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DYSPEPSIA; FAINTNESS; FEMALE; FEVER; FLUSHING; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; LOOSE FECES; LOW BACK PAIN; MALE; MONOTHERAPY; MYALGIA; NAUSEA AND VOMITING; NORMAL HUMAN; RASH; SIDE EFFECT; SINGLE DRUG DOSE; SKIN TINGLING; SMELLING DISORDER; STEADY STATE; TANDEM MASS SPECTROMETRY; TASTE DISORDER; VOLUNTEER;

AGED; ANTIBIOTICS, ANTITUBERCULAR; AREA UNDER CURVE; CROSS-OVER STUDIES; DRUG INTERACTIONS; FEMALE; FLUOROQUINOLONES; HUMANS; ISONIAZID; MALE; MIDDLE AGED; PYRAZINAMIDE; RIFAMPIN;

EID: 36448933803     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm393     Document Type: Article

References (12)

1. Hu Y, Coates ARM, Mitchison DA. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003; 47 653-7.
2. Nueremberger EL, Yoshimatsu T, Tyagi S et al. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Cdt Care Med 2004; 169: 421-6.
3. Johnson JL, Hadad DJ, Boom WH et al. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2006; 10: 605-12.
4. Nakashima M, Uematsu T, Kosuge K et al. Single- and multipledose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans. Antimicrob Agents Chemother 1995; 39: 2635-40.
5. Grasela DM. Clinical pharmacology of gatifloxacin, a new fluoroquinolone. Clin infect Dis 2000; 31 Suppl: 51-8.
6. Ishiwata Y, Sanada Y, Yasuhara M. Effects of gatifloxacin on serum glucose concentration in normal and diabetic rats. Biol Pharm Bull 2006; 29: 527-31.
7. Diacon AH, Patientia RF, Venter A et al. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob Agents Chemother 2007; 51: 2994-6.
8. Long MW, Snider DE, Farer LS. U.S. Public Health Service cooperative trial of three rifampin-isoniazid regimens in treatment of tuberculosis. Am Rev Respir Dis 1979; 119: 879-94.
9. Gurumurthy P, Ramachandran G, Hemanth Kumar AJ et al. Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease. Antimicrob Agents Chemother 2004; 48: 4473-5.
10. Mcllleron H, Wash P, Burger A et al. Determinants of rifampicin, isoniazid, pyrazinamide and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob Agents Chemother 2006; 50: 1170-7.
11. Tappero JW, Bradford WZ, Agerton TB et al. Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana. Clin Infect Dis 2005; 41: 461-9.
12. Weiner M, Burman W, Luo CC et al. Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin. Antimicrob Agents Chemother 2007; 51: 2861-6.